Big Pharma pursues epigenetics for cancer breakthroughs

Big Pharma companies like GlaxoSmithKline, Eli Lilly and Novartis are among the drugmakers pursuing new cancer treatments based on epigenetics--an approach that aims to reprogram abnormal DNA that causes cells to become cancerous. Epigenetics is already used in oncology drugs that treat certain blood-cancer disorders, but the real test will be to see whether it can also be applied to solid tumor cancers. Piece

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.